SCHEMBL7257752

SCHEMBL7257752

CCCCCCCCCCCCCCCCCCN(CCCCCCCCCCCCCCCCCC)C(=O)C(N)CC(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 11/20 0.44
S1PR1 P21453 2/20 0.44
S1PR2 O95136 1/20 0.44
S1PR3 Q99500 1/20 0.41
GRIK1 P39086 1/20 0.40
GRIK2 Q13002 1/20 0.40
PPARG P37231 6/20 0.39
PPARD Q03181 6/20 0.39
PPARA Q07869 6/20 0.39
HDAC11 Q96DB2 5/20 0.39
TSHR P16473 4/20 0.39
ALDH1A1 P00352 2/20 0.39
TLR2 O60603 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FABP4 P15090 2/20 0.39
PTPN1 P18031 2/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
MEN1 O00255 1/20 0.39
ESR1 P03372 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27902175 1.00 GPR84 (0.44) GPR84S1PR1S1PR2S1PR3GRIK1
SCHEMBL3806233 1.00 GPR84 (0.44) GPR84S1PR1S1PR2S1PR3GRIK1
SCHEMBL7260987 1.00 GPR84 (0.44) GPR84S1PR1S1PR2S1PR3GRIK1
SCHEMBL9316477 0.93 CA12 (0.42) GPR84S1PR1S1PR2S1PR3GRIK1
SCHEMBL9316473 0.93 CA12 (0.42) GPR84S1PR1S1PR2S1PR3GRIK1
SCHEMBL6659268 0.83 S1PR2 (0.48) GPR84S1PR1S1PR2S1PR3PPARG
SCHEMBL7572689 0.83 S1PR2 (0.48) GPR84S1PR1S1PR2S1PR3PPARG
SCHEMBL7565565 0.83 S1PR2 (0.48) GPR84S1PR1S1PR2S1PR3PPARG
SCHEMBL7565141 0.83 S1PR2 (0.48) GPR84S1PR1S1PR2S1PR3PPARG
SCHEMBL6535151 0.83 S1PR2 (0.48) GPR84S1PR1S1PR2S1PR3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6638529-B2 Lipid copound for use in the transfer macromolecules in cells GENTA INCORPORATED 2003-10-28 US disclosed
US-20020156237-A1 Novel amide-based cationic lipids PROMEGA BIOSCIENCES, INC. 2002-10-24 US disclosed
US-6339173-B1 FOR INTERFERING WITH PROTEIN EXPRESSION IN A CELL; USEFUL IN LIPID AGGREGATES FOR THE DELIVERY OF MACROMOLECULES INTO CELLS PROMEGA BIOSCIENCES, INC. 2002-01-15 US disclosed
US-6020526-A Amide-based cationic lipids GENTA, INCORPORATED (US) 2000-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156237-A1 Novel amide-based cationic lipids CETP, SGMS1, CERT1 GPR84 1152/4885S1PR1 285/4885S1PR2 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.